Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Abstract Background Treatment with brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a high objective response rate (93%) and complete response rate (67%) in 60 patients with relapsed/refractory mantle cell lymphoma (R/R MCL)...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Javier Muñoz, Frederick L. Locke, Patrick M. Reagan, Andre Goy, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Wangshu Zhang, Rhine R. Shen, Rita Damico Khalid, Ioana Kloos, Michael L. Wang
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	BMC 2026-04-01
श्रृंखला:	Journal of Hematology & Oncology
विषय:	Brexu-cel CAR T-cell therapy Mantle cell lymphoma ZUMA-2 Long-term follow-up
ऑनलाइन पहुंच:	https://doi.org/10.1186/s13045-026-01797-4
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!